Company news

Mind Cure Health Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology

March 19, 2021

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

March 15, 2021

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study

March 9, 2021

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

March 4, 2021

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research

March 3, 2021

MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin

March 2, 2021

Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors

February 22, 2021

MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform

February 18, 2021

Mind Cure Comments on Recent Promotional Activity

February 17, 2021

Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics

February 17, 2021

MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization

February 16, 2021

MINDCURE Announces Listing of Warrants

February 11, 2021

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

February 10, 2021

MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category

January 26, 2021

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering

January 22, 2021

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering

January 22, 2021

Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering

January 21, 2021

MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index

January 21, 2021

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

January 12, 2021

Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research

January 6, 2021

Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club

December 31, 2020

Mind Cure Announces Novel Supplement Product to Address Teen Wellness

December 29, 2020

Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy

December 10, 2020

Mind Cure Health Inc. Announces Participation in the Benzinga Global Small Cap Conference

December 9, 2020

Mind Cure Announces its Research Program with Psychedelic Compounds

December 8, 2020

Mind Cure Announces Eligibility for DTC Trading

December 2, 2020

Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer

December 1, 2020

Mind Cure Announces Closing of Oversubscribed $3.6 Million Offering

November 19, 2020

Mind Cure Announces Non-Brokered Private Placement of $3 Million

November 13, 2020

Mind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer

November 10, 2020

Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health

October 21, 2020

Mind Cure Announces Geoff Belair as Chief Technology Officer

October 15, 2020

Mind Cure Announces Addition of Neuroscientist Dr. Wolfram Tetzlaff to Scientific Advisory Board

October 13, 2020

Health and Wellness Industry Tastemaker Jon Bier Joins Mind Cure's Advisory Board

October 8, 2020

Mind Cure Welcomes Dr. Jason Wallach to Scientific Advisory Board

October 7, 2020

Mind Cure Welcomes Award-Winning Journalist and Science Researcher Hamilton Morris to Advisory Board

October 6, 2020

Dr. Dan Engle Joins Mind Cure's Advisory Board

October 1, 2020

Mind Cure Announces Kelsey Ramsden as new Chief Operating Officer

September 29, 2020

Mind Cure adds Alain Roy as a product development specialist

September 24, 2020

Mind Cure Receives Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada

September 23, 2020

Mind Cure announces commencement of trading on the CSE

September 21, 2020

Mind Cure Announces Closing of Oversubscribed Upsized Initial Public Offering

September 17, 2020

CSE Bulletin: Appointment of Market Maker - Mind Cure Health Inc. (MCUR)

September 16, 2020

← Newer news releases